Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts

British Journal of Plastic Surgery

Volumn 56, Issue 8, 2003, Pages 804-809

  Giugliano, G ^a   Pasquali, D ^a   Notaro, A ^a   Brongo, S ^a   Nicoletti, G ^a   D'Andrea, F ^a   Bellastella, A ^a   Sinisi, A A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cellular growth; Interleukin 6; Keloid fibroblasts; Morphological examination; Vascular endothelial growth factor; Verapamil

Indexed keywords

CALCIUM ANTAGONIST; INTERLEUKIN 6; VASCULOTROPIN; VERAPAMIL;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SHAPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROBLAST; FIBROBLAST CULTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOTHESIS; IN VIVO STUDY; KELOID; PRIORITY JOURNAL; PROTEIN SECRETION; STATISTICAL ANALYSIS;

EID: 0344034678     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0007-1226(03)00384-9     Document Type: Article

References (26)

1. Datubo-Brown DD. Keloids: a review of the literature. Br J Plast Surg 1990;43:70-7.
2. Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg 1989;84: 827-37.
3. Ehrlich HP, Desmouliere A, Diegelmann RF, et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol 1994; 145:105-13.
4. Abergel RP, Pizzurro D, Merker CA, et al. Biochemical composition of the connective tissue in keloids and analysis of collagen metabolism in keloid fibroblast cultures. J Invest Dermatol 1985;84:384-90.
5. Luo S, Benthan M, Raffoul W, Panizzon RG, Egloff DV. Abnormal balance between proliferation and apoptotic cell death in fibroblasts derived from keloid lesions. Plast Reconstr Surg 2001; 107:87-96.
6. Lim IJ, Phan TT, Song C, Tan WT, Longaker MT. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg 2001; 107:797-808.
7. Rumalla VK, Borah GL. Cytokines, growth factors, and plastic surgery. Plast Reconstr Surg 2001; 108:719-33.
8. Xue H, McCauley RL, Zhang W. Elevated interleukin-6 expression in keloid fibroblasts. J Surg Res 2000;89:74-7.
9. Steinbrech DS, Mehrara BJ, Chau D, et al. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg 1999;42:514-9.
10. Darzi MA, Chowdri NA, Kaul SK, Khan M. Evaluation of various methods of treating keloids and hyperptrophic scars. A 10-year follow-up study. Br J Plast Surg 1992;45:374-9.
11. D'Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2002; 204:60-2.
12. Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. Ann Plast Surg 1996;37:167-9.
13. Lee RC, Doong H, Jellama AF. The response of burn scars to intralesional verapamil: report of five cases. Arch Surg 1994; 129:107-11.
14. Lee RC, Ping J. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990;49:463-6.
15. Lee RC, Doong H, Jellama AF. Stimulation of dermal scar matrix degradation in situ with a fibroblast L-type calcium channel blocker. In Proceedings of the Meeting of the American Association of Plastic Surgery. Vancouver, 1992.
16. Doong H, Dissanayake S, Gowrishankar TR, La Barbera MC, Lee RC. The 1996 Limdberg Award: calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil 1996; 17:497-514.
17. 2+-induced mitogen-activated protein kinase activation in human fibroblast. Cell Signal 1999; 11:263-74.
18. Kang Y, Lee DA, Higginbotham EJ. In vitro evaluation of antiproliferative potential of calcium channel blockers in human Tenon's fibroblast. Exp Eye Res 1997;64:913-25.
19. Mateo RB, Reichner JS, Albina JE. Interleukin-6 activity in wound. Am J Physiol 1994; 266(6 Pt. 2): R1840-4.
20. Turksen K, Kupper T, Degenstein L, Williams I, Fuchs E. Interteukin-6: insights to its function in skin by over-expression in transgenic mice. Proc Natl Acad Sci USA 1992;89:5068-72.
21. Gallucci RM, Simeonova PP, Matheson JM, et al. Impaired cutaneuos wound healing in interleukine-6-deficient and immuno-suppressed mice. FASEB J 2000; 14:2525-31.
22. Sawamura D, Meng X, Ina S, et al. Induction of keratinocytes proliferation and lymphocytic infiltration by in vivo introduction of the IL-6 gene into keratinocytes and possibility of keratinocyte gene therapy for inflammatory skin diseases using IL-6 mutant genes. J Immunol 1998; 161:5633-9.
23. Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, Di Pietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative stage of wound healing. Am J Pathol 1998; 152:1445-52.
24. Taub PJ, Silver L, Weinberg H. Plastic surgical perspectives on vascular endothelial growth factor as gene therapy for angiogenesis. Plast Reconstr Surg 2000; 105:1034-42.
25. Frank S, Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J. Nitric oxide trigger enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J 1999; 13:2002-14.
26. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.